Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-01-06
1998-03-24
Jarvis, William R.A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514277, 514344, 514357, A61K 31505, A61K 3144, A61K 31435
Patent
active
057313148
ABSTRACT:
Patients susceptible to or suffering from Tourette's syndrome are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and
REFERENCES:
patent: 3870794 (1975-03-01), Hutchinson et al.
patent: 4680172 (1987-07-01), Leeson
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5219872 (1993-06-01), Galliani et al.
patent: 5219873 (1993-06-01), Galliani et al.
patent: 5225567 (1993-07-01), Moon et al.
Adler, L. et al., "Normalization by Nicotine of Deficient Auditory Sensory Gating in the Relative Schizophrenics", Biol. Psychiatry, vol. 32, pp. 607-616 (1992).
Calderon-Gonzalez R., "Tourette Syndrome", Intern. Pediat., vol. 8(2), pp. 176-188 (1993).
Decina, P. et al., "Cigarette Smoking and Neuroleptic-Induced Parkinsonism", Biol. Psychiatry, 28, pp. 502-508 (1990).
Devor, E. et al., "Nicotine and Tourette's Syndrome", The Lancet, vol. 8670, pp. 1046 (1989).
Faraone, S. et al., "An Exploratory Study of ADHD among Second-Degree Relatives of ADHD Children", Biol. Psychiatry, vol. 35(6), pp. 398-402 (1994).
Glassman, A., "Cigarette Smoking: Implications for Psychiatric Illness", Am J Psychiatry, vol. pp. 546-553 (1993).
Hall, G. et al., "Effects of Nicotine on the Release of .sup.3 H-Noradrenaline form the Hypothalamus" Biochemical Pharmacology, vol. 21, pp. 1829-1838 (1972).
Harsing, L. et al., "Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autore Desensitization", Journal of Neurochemistry, vol. 59, pp. 48-54 (1993).
Hery, F. et al., "Control of the Release of Newly Synthetized .sup.3 H-5-Hydroxytryptamine by Nicoti and Muscarinic Receptors in Rat Hypothalamic Slices", Arch. Int. Pharmacodyn. Ther., vol. 29 91-97 (1977).
Jarvik, M. "Beneficial effects of nicotine", British Journal of Addiction, vol. 86, pp. 571-575 (1991).
Lieberman, J. et al., "Neurochemistry and Neuronendocrinology of Schizophrenia: A Selective Review", Schizophr. Bull., vol. 19, pp. 371-429 (1993).
Malone, M. et al., "Hemispheric Processing and Methylphenidate Effects in Attention-Deficit Hyperactivity Disorder", J. Child Neurol., vol. 9(2), pp. 181-189 (1994).
Hughes, "Proceedings from Intl. Symp. Nic.", S40 (1994).
McConville, B. et al., "Nicotine Potentiation of Haloperidol in Reducing Tic Frequency in Tourette's Disorder", Am. J. Psychiatry, vol. 148, pp. 793-794 (1991).
McConville, B. et al., "The Effects of Nicotine Plus Haloperidol Compared to Nicotine Only and Placebo Nicotine Only in Reducing Tic Severity and Frequency in Tourette's Disorder", Biol. Psychiatry, vol. 31, pp. 832-840 (1992).
Newhouse, P. et al., "The role of nicotine and nicotinic mechanisms in neuropsychiatric disease", British Journal of Addiction, vol. 86, pp. 521-526 (1991).
Onaivi, E. et al., "Chronic Nicotine Reverses Age-Associated Increases in Tail-Flick Latency and Anxiety in Rats", Life Sciences, vol. 54, pp. 193-202 (1994).
Perry E., "The Cholinergic Hypothesis-Ten Years On", British Medical Bulletin, vol. 42, pp. 63-69 (1986).
Rapier, C. et al., "Stereoselective Nicotine-Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation", Journal of Neurochemistry, vol. 50, pp. 1123-1130 (1988). Release from Mouse Cerebral Cortical Synaptosomes", Journal of Neurochemistry, vol. 43, pp. 1593-1598 (1984).
Sanberg, P. et al., "Nicotine Potentiation of Haloperidol-Induced Catalepsy: Striatal Mechanisms", Pharmacology Biochemistry and Behavior, vol. 46, pp. 303-307 (1993).
Sandor, N. et al., "Effect of nicotine on dopaminergic-cholinergic interaction in the striatum", Brain Research, vol. 567, pp. 313-316 (1991).
Sitaram, N. et al., "Human Serial Learning: Enhancement with Arecholine and Choline and Impairment with Scopolamine", Science, vol. 201, pp. 274-276 (1978).
Sjak-Shie, N. et al., "Effects of chronic nicotine and pilocarpine in nucleus basalis lesioned rats", Brain Research, vol. 624, pp. 295-298 (1993).
Toth, E. et al., "Effect of Nicotine on Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid", Neurochemical Research, vol. 17(3), pp. 265-271 (1992).
Vizi, E., "Acetylcholine release from guinea-pig ileum by parasympathetic ganglion stimulants and gastrin-like polypeptides", British Journal Pharmacology, vol. 47, pp. 765-777 (1973).
Physicians' Desk Reference, 48 Edition, p. 410-411 (1994), "Cylert".
Physicians' Desk Reference, 48 Edition, p. 520-523 (1994), "Prolixin".
Physicians' Desk Reference, 48 Edition, p. 612-614 (1994), "Catapres".
Physicians' Desk Reference, 48 Edition, p. 835-836 (1994), "Ritalin".
Physicians' Desk Reference, 48 Edition, p. 977-979 (1994), "Orap".
Physicians' Desk Reference, 48 Edition, p. 1357-1359 (1994), "Haldol".
Physicians' Desk Reference, 48 Edition, p. 1935-1936 (1994), "Klonopin".
Physicians' Desk Reference, 48 Edition, p. 2248-2250 (1994), "Dexedrine".
Hechtman, L., "Genetic and Neurobiological Aspects of Attention Deficit Hyperactive Disorder: A Review", J. Psychiatry Neurosci., vol. 19(3), pp. 193-201 (1994).
Merriam, et al., "Schizophrenia as a Neurobehavioral Disorder", Psychiatr. Annals., vol. 23, p. 178 (1993).
Pomerleau, et al., "The Effects of Cigarette Smoking on Pain and Anxiety", Addictive Behavi 9, p. 265 (1984).
Sanberg, et al., Proceedings from Intl. Symp. Nic., S39 (1994).
Vinson, D., "Therapy for Attention-Deficit Hyperactivity Disorder", Arch. Fam. Med., vol. 3(5), 445-451 (1994).
Wagner, et al., "Does Smoking Reduce the Risk of Neuroleptic Parkinsolnoids?", Pharmacopsychiatry, vol. 21, pp. 301-303 (1988).
Warburton, et al., "Cholinergic control of cognitive resources", Neuropsychobiology, Eds. Mendlewicz, et al., pp. 43-46 (1993).
Freedman, R. et al., Proceedings from Intl. Symp. Nic., S41 (1994).
Repond et al, Arzneim.-Forsch./Drug Research 36(II), No. 8 (1986), pp. 1191-1194.
Bencherif Merouane
Caldwell William Scott
Dull Gary Maurice
Lippiello Patrick Michael
LandOfFree
Pharamceutical compositions for prevention and treatment of tour does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharamceutical compositions for prevention and treatment of tour, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharamceutical compositions for prevention and treatment of tour will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2289115